## MTD: Mettler-Toledo International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.2% below STRENGTH zone (3.0-6.0%); PEG 5.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1347.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Skandinaviska Enskilda Banken AB publ Sells 2,577 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251202T113248 | Neutral | Relevance: 100%
- Skandinaviska Enskilda Banken AB publ has reduced its stake in Mettler-Toledo International, Inc. (NYSE:MTD) by 29.7%, selling 2,577 shares and now owning 6,103 shares valued at approximately $7.17 million. This transaction comes amidst other institutional investor activity and recent insider selling, including CFO Shawn Vadala and Director Elisha W. Finney. Mettler-Toledo reported strong quarterly earnings, beating EPS estimates, and has a market capitalization of $30.17 billion.

**2. Arrowstreet Capital Limited Partnership Acquires 10,910 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251204T083213 | Somewhat-Bullish | Relevance: 100%
- Arrowstreet Capital Limited Partnership increased its stake in Mettler-Toledo International, Inc. by 19% in Q2, acquiring 10,910 additional shares, bringing its total holdings to 68,259 shares valued at approximately $80.2 million. This move coincides with several brokers raising price targets for Mettler-Toledo, though the consensus remains a "Hold" rating with an average price target of $1,419.55. The company recently surpassed quarterly earnings and revenue expectations and provided positive FY2025 guidance.

**3. Mettler-Toledo International (NYSE:MTD) Earns Equal Weight Rating from Analysts at Morgan Stanley**
- Source: MarketBeat | 20251203T141534 | Neutral | Relevance: 100%
- Morgan Stanley initiated coverage on Mettler-Toledo International (NYSE:MTD) with an "Equal Weight" rating and a $1,550 price target. The company recently beat Q3 earnings estimates and issued strong FY2025 guidance, but has seen significant insider selling. Other analysts hold a "Hold" consensus rating with various price target adjustments.

**4. New York State Common Retirement Fund Buys 3,015 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251203T123505 | Somewhat-Bullish | Relevance: 100%
- The New York State Common Retirement Fund increased its stake in Mettler-Toledo International, Inc. (NYSE:MTD) by 19.3%, acquiring 3,015 additional shares to hold a total of 18,660 shares worth $21.92 million. This move is part of broader institutional investor activity, with major firms like Vanguard and BNY Mellon also boosting their positions, resulting in institutional investors owning approximately 95.07% of the stock. Mettler-Toledo recently surpassed Q3 earnings expectations, reporting an EPS of $11.15 against an anticipated $10.62 and revenue of $1.03 billion, and has provided strong FY2025 EPS guidance, although analysts maintain a consensus "Hold" rating with a target price of $1,406.50.

**5. Mettler-Toledo International, Inc. $MTD Shares Sold by Schroder Investment Management Group**
- Source: MarketBeat | 20251202T120345 | Neutral | Relevance: 100%
- Schroder Investment Management Group reduced its stake in Mettler-Toledo International, Inc. (NYSE:MTD) by 12.7% in Q2 2025, selling 6,397 shares but still holding 43,989 shares valued at $51.7 million, while institutional investors combined own 95.07% of the company. Mettler-Toledo exceeded Q3 earnings estimates with an EPS of $11.15 and revenue of $1.03 billion, and analysts currently have a "Hold" rating on the stock with a $1,406.50 target price. Company insiders have also been net sellers, with the CEO and CFO collectively disposing of 3,000 shares recently, contributing to 19,565 shares worth about $28.68 million sold by insiders over the last 90 days.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $1550 | $0 | 0% |
| 2025-11-10 | Citigroup | $1700 | $1600 | +6% |
| 2025-11-10 | Barclays | $1600 | $1350 | +19% |
| 2025-11-10 | Wells Fargo | $1400 | $1200 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |
| 2025-11-10 | Citigroup | main | Buy |
| 2025-11-10 | Barclays | main | Overweight |
| 2025-11-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($1.28M) |
| Sells | 6 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+1.4%)
- Blackrock Inc.: 9.2% (-3.1%)
- State Street Corpora: 4.7% (-0.5%)
- Capital Internationa: 4.2% (+1.2%)
- Bank Of New York Mel: 4.0% (-9.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.2% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 5.9x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 5.87 signals overvaluation risk, limited margin of safety. Forward P/E 31.1x stretched relative to 8% growth. Quality metrics strong (ROE 30%, ROA 20%, margin 21%). Analyst sentiment positive (4 raises, avg +13%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $29.3B |
| Beta | 1.40 |
| 52W Range | $946.69 - $1525.17 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.87 |
| Forward P/E | 31.1 |
| Current P/E | 33.7 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.1% to -4.2% (-4.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.2pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.15x) but short-term weakness (below SMA20). MACD histogram bearish (-4.97), momentum weakening. RSI neutral at 49. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.24% (CS: 9) | Weak |
| RSI_14 | 49.4 | Neutral |
| MACD Histogram | -4.97 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 1.146x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1422.81
- **Stop Loss:** $1347.57 (5.3% risk)
- **Target:** $1498.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 6
- **Position Value:** $8,536.86
- **Portfolio %:** 8.54%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-05 (Est: $12.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $10.66 | $11.15 | +4.6% |
| 2025Q2 | $9.60 | $10.09 | +5.1% |
| 2025Q1 | $7.88 | $8.19 | +3.9% |
| 2024Q4 | $11.72 | $12.41 | +5.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*